KRAS and neoplasm: Targetable alterations in three genes were found in at least 5% of patients with high AJ ancestry: EGFR, KRAS, and MET. Strikingly, patients with high AJ ancestry were significantly more likely to harbor MET exon 14 skipping mutations and amplifications (OR = 2.1; 95% CI = 1.0–4.3, p = 0.039; Fig. 3C) after accounting for age at diagnosis, tumor histology, number of pack-years, and sex.